Table 1 Primary efficacy end point achievement and disease progression by country (pooled ITT population)
Country | AST-120 | Placebo | Placebo | |||||
|---|---|---|---|---|---|---|---|---|
N | n (%) | N | n (%) | Median Time a | eGFR decline b | eGFR at Dialysis Initiation c | ||
ALL | 1000 | 350 (35.0) | 999 | 360 (36.0) | 180.1 | −4.96 ± 9.50 | 10.47 ± 5.28 | |
NA | CAN | 61 | 22 (36.1) | 57 | 19 (33.3) | ND | −6.25 ± 9.56 | 10.65 ± 3.28 |
USA | 290 | 120 (41.4) | 293 | 129 (44.0) | 135.6 | −4.66 ± 11.42 | 13.95 ± 5.84 | |
LA | ARG | 73 | 20 (27.4) | 73 | 27 (37.0) | 135.7 | −5.17 ± 7.69 | 9.15 ± 2.47 |
BRA | 84 | 26 (31.0) | 83 | 25 (30.1) | ND | −3.13 ± 6.65 | 8.82 ± 3.39 | |
MEX | 58 | 21 (36.2) | 57 | 18 (31.6) | ND | −5.13 ± 8.35 | 7.45 ± 3.57 | |
EU | CZE | 21 | 6 (28.6) | 20 | 5 (25.0) | ND | −3.52 ± 3.02 | 11.91 ± 1.86 |
DEU | 7 | 2 (28.6) | 8 | 4 (50.0) | 119.3 | −3.49 ± 14.93 | 14.77 ± 3.29 | |
ESP | 8 | 3 (37.5) | 9 | 5 (55.6) | 71.3 | −4.20 ± 4.12 | 9.08 ± 1.24 | |
FRA | 17 | 5 (29.4) | 15 | 4 (26.7) | ND | −3.93 ± 7.59 | 11.24 ± 2.68 | |
ITA | 8 | 4 (50.0) | 7 | 2 (28.6) | ND | −2.60 ± 2.60 | 8.18 ± 1.80 | |
POL | 36 | 18 (50.0) | 38 | 15 (39.5) | ND | −3.50 ± 6.97 | 10.00 ± 3.23 | |
RUS | 173 | 57 (32.9) | 174 | 51 (29.3) | ND | −4.78 ± 7.73 | 7.32 ± 2.90 | |
UKR | 164 | 46 (28.0) | 165 | 56 (33.9) | ND | −7.17 ± 10.55 | 5.72 ± 2.67 | |